Home・Aandelen Lijst・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Open

SectorGezondheidszorg

9.69 3.75

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.34

Max

9.89

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.1B -722M
Verkoop	-250M 156M
K/W Sectorgemiddelde	7.603 62.58
EPS	0.14
Winstmarge	-461.478
Werknemers	435
EBITDA	-966M -700M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+134.37% upside

Dividenden
By Acuity
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-22M 2.3B
Vorige openingsprijs	5.94
Vorige sluitingsprijs	9.69

Nieuwssentiment

By Acuity

50%

146 / 340 Rangschikking in Healthcare

BioCryst Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22 jul 2026, 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21 jul 2026, 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20 jul 2026, 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Peer Vergelijking

Prijswijziging

BioCryst Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

134.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21.89 USD 134.37%

Hoogste 32 USD

Laagste 12 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioCryst Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan BioCryst Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

146 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.